Substantial improvements have been made in the management of metastatic colorectal
cancer over the last two decades. The overall survival of patients diagnosed with …

Background. Survival of patients with metastatic colorectal cancer (mCRC) has been
significantly improved with the introduction of the monoclonal antibodies targeting the …

Background The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus
bevacizumab showed improved outcomes for patients with metastatic colorectal cancer …

Background Advanced colorectal cancer is treated with a combination of cytotoxic drugs and
targeted treatments. However, how best to minimise the time spent taking cytotoxic drugs …

Purpose This phase II study evaluated the synthetic DNA-based immunomodulator and Toll-
like receptor 9 agonist MGN1703 as maintenance treatment in metastatic colorectal …

Systemic therapy is the standard care for patients with unresectable advanced colorectal
cancer (CRC), but salvage surgery of metastatic disease should be considered in the case …

In the last 20 years, improvements in metastatic colorectal cancer treatment lead to a radical
raise of outcomes with median survival reaching now more than 30 months. Despite that, the …

Oxaliplatin and fluoropyrimidines are synergic combinations very active for the treatment of
advanced colorectal cancer and for the adjuvant treatment of stage III colon cancer …

Background A dose-finding phase I/II trial that evaluated the maximum tolerated doses of a
combination of three drugs with irinotecan, oxaliplatin and capecitabine (COI regimen) has …

Background. After approval of bevacizumab in Germany in 2005 for the treatment of
unresectable advanced or refractory colorectal cancer (CRC), this observational cohort …